Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
$10.82
$0.10(1.66%)
At close: 4:00 PM EST
$10.82
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$4.60 - $14.93
Previous CloseN/A
Volume37.28K
Average Volume (3M)77.23K
Market Cap
$199.05M
Enterprise Value$185.59M
Total Cash (Recent Filing)$18.56M
Total Debt (Recent Filing)$5.11M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 20, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding18,396,074
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-219.11
Enterprise Value/Ebitda-5.07
Forecast
1Y Price Target
$17.33Price Target Upside60.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ImmunogenicityELI-002 elicited strong KRAS-specific T-cell responses in nearly all evaluable pancreatic cancer patients, supporting the vaccine's potential to reduce recurrence and improve survival.
Platform Commercial PotentialThe Amphiphile delivery technology targets neoantigen peptides to lymph nodes and could be licensed or partnered with larger companies as a new revenue source beyond the company's own programs.
Regulatory PathwayPositive interim Phase 2 results would lead management to seek an End-of-Phase 2 meeting with the FDA to define a pivotal Phase 3 design, clarifying the path toward potential approval.
Bears Say
Cash Runway RiskModest cash reserves relative to projected development costs imply additional financing may be required to fund later-stage programs, creating a valuation and execution risk.
Financing Need And DilutionPlanned capital raising to initiate a pivotal Phase 3 creates a financing need that could dilute existing shareholders if trial results do not justify the investment.
Trial Timing UncertaintyThe trial has not reached the required number of relapse and death events, delaying the data readout and prolonging uncertainty about clinical outcomes.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $4.60 and its highest was $14.93 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $199.05M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 54 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.445 by -$0.005.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 18,396,074 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.445. Following the earnings report the stock price went up 11.927%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.01%
12-Months-Change
Fundamentals
Return on Equity
-977.67%
Trailing 12-Months
Asset Growth
-8.22%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$17.33
▲(60.17% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
31.69% Insiders
2.89% Mutual Funds
6.03% Other Institutional Investors
56.51% Public Companies and
Individual Investors